Nebenwirkungen · Degevma
Degevma 120 mg solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-152296 · Präparat HOS-100725
The following convention has been used for the classification of the adverse reactions based on incidence rates in four phase III, two phase II clinical studies and post-marketing experience (see table 1): very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping and system organ class, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T11:32:00Z · SHA-256 42d5e2a42bc26ec6cfe17bc16a0b6c7aefac65193465706eb459c472cc75aee0 · Passage d8c2fdebe668198a39611ddeb52b4fce43d8c968507dc5d837ca13ab5ff1c13a · Zeichen 716–1243 im Abschnitt